Sugi Predict

Sugi Predict / Compounds / SCHEMBL8429622

SCHEMBL8429622

SCHEMBL8429622

Cc1ccccc1-c1nn[nH]n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 1.00
▸ L3MBTL1 Q9Y468 2/20 0.73
▸ ALDH1A1 P00352 2/20 0.73
▸ KMT2A Q03164 2/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ PBRM1 Q86U86 1/20 0.61
▸ IDO1 P14902 1/20 0.61
▸ LDHA P00338 1/20 0.61
▸ CLCN2 P51788 1/20 0.51
▸ XDH P47989 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ HPGDS O60760 1/20 0.49
▸ PDE3B Q13370 1/20 0.48
▸ PDE3A Q14432 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylbiphenyl Tetrazole SCHEMBL8171721 0.78 MEN1 (0.69) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL29022629 0.77 GAA (0.61) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL3397464 0.76 ALDH1A1 (0.73) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL8294492 0.76 ALDH1A1 (0.73) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL2645790 0.76 ALDH1A1 (0.73) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL8294486 0.76 LDHA (1.00) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL14844440 0.76 ALDH1A1 (0.73) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL14262602 0.76 MEN1 (0.73) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL4206359 0.76 PBRM1 (1.00) GAAL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL30153550 0.76 MEN1 (0.80) GAAL3MBTL1ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 — — US disclosed
EP-2861568-B1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIV OSLO (NO) 2019-04-17 — — EP disclosed
US-9809545-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-07 — — US disclosed
EP-2978425-B1 FACTOR XIA INHIBITORS MERCK SHARP & DOHME (US) 2017-09-27 — — EP disclosed
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2017-06-08 — — US disclosed
US-9585880-B2 Cyclic amino compounds for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-03-07 — — US disclosed
US-9556111-B2 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO (NO) 2017-01-31 — — US disclosed
US-20160046581-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-02-18 — — US disclosed
US-20150141456-A1 CYCLIC AMINO COMPOUNDS FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-21 — — US disclosed
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS UNIVERSITETET I OSLO (NO) 2015-05-14 — — US disclosed
US-20100256109-A1 Azetidines As EP2 Antagonists SKERRATT SARAH ELIZABETH 2010-10-07 — — US disclosed
US-20080119657-A1 PHENYLTETRAZOLE COMPOUNDS DIPHARMA S. P. A. (IT) 2008-05-22 — — US disclosed
US-7345072-B2 Phenyltetrazole compounds DIPHARMA S.P.A. (IT) 2008-03-18 — — US disclosed
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS DIPHARMA S.P.A. (IT) 2007-04-26 — — US disclosed
US-20040102472-A1 Method of preparing inhibitors of phosphodiesterase-4 MERCK & CO., INC. 2004-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102472-A1 Method of preparing inhibitors of phosphodiesterase-4 PDE4B, PDE4A, PDE5A GAA 500/4885L3MBTL1 4862/4885ALDH1A1 558/4885
US-20080119657-A1 PHENYLTETRAZOLE COMPOUNDS ACE, AGTR2, ACE2 GAA 770/4885L3MBTL1 4669/4885ALDH1A1 1607/4885
US-20160046581-A1 Factor XIa Inhibitors F11, F12, TFPI GAA 1898/4885L3MBTL1 4518/4885ALDH1A1 2920/4885
US-20100256109-A1 Azetidines As EP2 Antagonists PTGER2, PTGER1, PTGDR2 GAA 4531/4885L3MBTL1 4875/4885ALDH1A1 544/4885
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 GAA 1962/4885L3MBTL1 3117/4885ALDH1A1 3412/4885
US-20070093540-A1 PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS AGTR2, AGTR1, ACE2 GAA 1065/4885L3MBTL1 4866/4885ALDH1A1 2207/4885
US-20170158657-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 GAA 1759/4885L3MBTL1 2957/4885ALDH1A1 1367/4885
US-20150133510-A1 TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, MYLK2 GAA 1800/4885L3MBTL1 2589/4885ALDH1A1 1191/4885
US-20150141456-A1 CYCLIC AMINO COMPOUNDS FOR USE IN THE TREATMENT OF CARDIAC DISORDERS TNNI3, TNNT2, AKAP8L GAA 3143/4885L3MBTL1 2679/4885ALDH1A1 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.